Retatrutide

Retatrutide is a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Research demonstrates differential receptor activation profiles compared to dual agonists. Subject of in-vitro and preclinical studies involving adipose tissue, hepatic lipid accumulation, and glycemic signaling. Supplied as lyophilized powder for research use only.

Research Use Only. All products sold on this website are strictly for laboratory research, in-vitro testing, and analytical purposes only. Products are not intended for human consumption, diagnostic, therapeutic, or any medical applications. Not evaluated or approved by the FDA.